This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

TRACON Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Craig Jalbert

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4yrs
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Sep 06

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Aug 29

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

Dec 10

Tracon Pharma files China application for envafolimab in solid tumors

Nov 16

CEO

Craig Jalbert (62 yo)

less than a year

Görev süresi

Mr. Craig R. Jalbert serve as a CEO, President, Chief Financial Officer, Treasurer and Secretary and sole member of the board since November 2024 at TFF Pharmaceuticals, Inc. He is President, Treasurer, CS...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Brown	Chief Financial Officer	5.9yrs	US$590.49k	0.037% $ 40.4
Craig Jalbert	CEO, President	less than a year	Veri yok	Veri yok
James Freddo	Chief Medical Officer	4.6yrs	Veri yok	Veri yok
Ya Huang	Executive Director of Statistical Programming	3.5yrs	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: TCON 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/04 21:10
Gün Sonu Hisse Fiyatı	2024/12/02 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

TRACON Pharmaceuticals, Inc. 12 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Matthew Cross	Alliance Global Partners
Joel Beatty	Baird
null null	BTIG

This company listing is no longer active

TRACON Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of Directors

Tracon Pharmaceuticals, Inc. Announces Executive Changes

Recent updates

TRACON Pharmaceuticals, Inc. Common Stock to Be Deleted from OTC Equity

TRACON Pharmaceuticals Files Form 15

TRACON Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals Announces It Will Wind Down Operations

TRACON Pharmaceuticals Notifies Nasdaq of its Withdrawal of the Appeal

TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform

TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index

Investor sentiment improves as stock rises 16%

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

Price target decreased by 19% to US$30.50

Forecast to breakeven in 2026

TRACON Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

Insufficient new directors

New major risk - Share price stability

New major risk - Shareholder dilution

TRACON Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

Consensus EPS estimates upgraded to US$0.45 loss

TRACON Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Share price stability

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

New major risk - Financial position

Consensus revenue estimates increase by 50%

TRACON Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value Rule and Minimum Bid Price Requirement

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

TRACON Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 10, 2023

Price target decreased by 12% to US$9.33

No longer forecast to breakeven

TRACON Pharmaceuticals Receives A Letter from Nasdaq Regarding Market Value Rule

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals, Inc Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

Price target decreased to US$10.20

TRACON Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from Envasarc Phase 2 Pivotal Trial

TRACON Pharmaceuticals Announces Fast Track Designation by the Food and Drug Administration for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and TRACON Pharmaceuticals, Inc. Announce U.S. Food and Drug Administration Approval of Investigational New Drug

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Consensus forecasts updated

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

TRACON Pharmaceuticals, Inc. Submits IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-Line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

TRACON Pharmaceuticals Announces Dosing of 36Th Patient in Envasarc Pivotal Trial Triggering Initial Idmc Efficacy Review Expected in the Fourth Quarter

Consensus revenue estimates increase by 99%

TRACON Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Forecast to breakeven in 2024

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K

No longer forecast to breakeven

No longer forecast to breakeven

TRACON Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 15, 2022

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Reports Regulatory Approval of Envafolimab in China

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of Directors

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.805977 million.

TRACON Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Tracon Pharmaceuticals, Inc. Announces Executive Changes